Second line biological therapy in paediatric IBD: Effective but carries significant financial and safety implications.

Adalimumab Study Grp B, D. Wilson, M. Wilson, R. Russell

Research output: Contribution to journal › Book/Film/Article review › peer-review

Original language	English
Pages (from-to)	S39-S39
Number of pages	1
Journal	Inflammatory Bowel Diseases
Volume	17
Publication status	Published - Jan 2011

Cite this

@article{46a762c3f0e1457ea6ad81d4b9ddc9e0,

title = "Second line biological therapy in paediatric IBD: Effective but carries significant financial and safety implications.",

author = "{Adalimumab Study Grp B} and D. Wilson and M. Wilson and R. Russell",

year = "2011",

month = jan,

language = "English",

volume = "17",

pages = "S39--S39",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Wiley",

}

TY - JOUR

T1 - Second line biological therapy in paediatric IBD: Effective but carries significant financial and safety implications.

AU - Adalimumab Study Grp B

AU - Wilson, D.

AU - Wilson, M.

AU - Russell, R.

PY - 2011/1

Y1 - 2011/1

M3 - Book/Film/Article review

SN - 1078-0998

VL - 17

SP - S39-S39

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

ER -